Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares are up during Tuesday’s premarket session as the company announced a public offering of 12.5 million shares at an offering price of $1.40.
This move is expected to generate gross proceeds of $17.5 million.
Offering Structure Includes Warrants
Inovio plans to sell 12.5 million shares of common stock along with Series A and Series B warrants to purchase up to 12.5 million shares at a price of $1.40 each.
Cash Position Supports Operations Into Late 2026
In March, Inovio reported a fourth-quarter diluted loss of 26 cents per share, better than the 38-cent analyst consensus cited by Benzinga and improved from a 65-cent loss a year earlier.
For full-year 2025, the company posted a net loss of $84.9 million, compared with $107.3 million in 2024, while total operating expenses fell to $86.9 million from $112.6 million.
The company ended 2025 with $58.5 million in cash, cash equivalents, and short-term investments and said current resources are expected to fund operations into the fourth quarter of 2026, including an estimated first-quarter 2026 operational net cash burn of about $22 million.
FDA Review For INO-3107
In December 2025, the U.S. Food and Drug Administration accepted Inovio’s Biologics License Application (BLA) for INO-3107 but raised concerns tied to the accelerated approval pathway.
The biotechnology company focused on developing and commercializing DNA medicines said that the FDA accepted the company's BLA for INO-3107 for review as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The review classification designated by the FDA is Standard.
RRP is a rare, benign (noncancerous) disease caused by the Human Papillomavirus, leading to wart-like tumors in the respiratory tract, most commonly the larynx (voice box).
INO Stock Price Activity: Inovio Pharmaceuticals shares were down 0.88% at $1.12 during premarket trading on Tuesday, according to Benzinga Pro data.
Image via Shutterstock